Systemic lupus erythematosus

Summer Fellowship Grants Support Young Scientists' Innovative Lupus Research Studies

Retrieved on: 
Thursday, July 16, 2020
Medical specialties, Medicine, Health, Lupus Foundation of America, RTT, Autoimmune diseases, Autoantibodies, Systemic lupus erythematosus, Lupus, Anti-SSA/Ro autoantibodies, Autoimmune disease

Lupus is an unpredictable and misunderstood autoimmune disease that ravages different parts of the body.

Key Points: 
  • Lupus is an unpredictable and misunderstood autoimmune disease that ravages different parts of the body.
  • Lupus is debilitating and destructive and can be fatal, yet research on lupus remains underfunded relative to diseases of similar scope and devastation.
  • The Lupus Foundation of America is the national force devoted to solving the mystery of lupus, one of the world's cruelest, most unpredictable and devastating diseases, while giving caring support to those who suffer from its brutal impact.
  • Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus.

Antilupus Drug Prevents Low Heartbeat Condition in Newborns

Retrieved on: 
Monday, July 13, 2020
Medical specialties, Branches of biology, Anatomy, RTT, Cutaneous lupus erythematosus, Systemic lupus erythematosus, William Osler, Anti-SSA/Ro autoantibodies, Fetus, Antibody, CHB, Heart

The condition, called congenital heart block (CHB), results in a lower than normal heart rate and affects as many as one in 15,000 live births, study investigators say.

Key Points: 
  • The condition, called congenital heart block (CHB), results in a lower than normal heart rate and affects as many as one in 15,000 live births, study investigators say.
  • Of the babies born with low heart rates who survive, about 75 percent will require at least one pacemaker during their lifetime.
  • CHB is strongly linked to the presence of immune proteins, or antibodies, in the mother that react with other proteins called SSA/Ro.
  • The drug reduces tissue inflammation, the main feature of SLE, and what researchers believe injures the fetal heart, leading to CHB.

Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded

Retrieved on: 
Monday, July 13, 2020
Medical specialties, Medicine, Autoimmune diseases, Clinical medicine, TLR7, Systemic lupus erythematosus, Anti-SSA/Ro autoantibodies, Autoimmunity, Lupus erythematosus, Autoantibody, Epratuzumab

This joint research project was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program.

Key Points: 
  • This joint research project was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program.
  • In this project, Eisai aims at creating a Japan-originated therapeutic drug for systemic lupus erythematosus (SLE) through industry-academia-government collaboration, using its in-house discovered new oral Toll-Like Receptor (TLR) 7/8 inhibitor E6742.
  • E6742 has selective and potent inhibitory activity against TLR7/8, and is expected to potentially become a new therapeutic agent for SLE.
  • Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease induced by antibodies that causes various organ disorders involving disorders of the skin and the musculoskeletal system.

Lupus Foundation of America Survey Finds Over Half of Respondents Experienced Issues Accessing Hydroxychloroquine During Coronavirus Pandemic

Retrieved on: 
Tuesday, June 23, 2020
Medical specialties, RTT, Medicine, Health, Hydroxychloroquine, Antimalarial medication, Chloroquine, Systemic lupus erythematosus, Rheumatoid arthritis, Arthritis, Coronavirus

WASHINGTON, June 23, 2020 /PRNewswire/ --In a new survey conducted by the Lupus Foundation of America, 55% of respondents taking antimalarials to manage their lupus reported having difficulty accessing their prescription for hydroxychloroquine or chloroquine, during March May 2020 of the coronavirus (COVID-19) pandemic.

Key Points: 
  • WASHINGTON, June 23, 2020 /PRNewswire/ --In a new survey conducted by the Lupus Foundation of America, 55% of respondents taking antimalarials to manage their lupus reported having difficulty accessing their prescription for hydroxychloroquine or chloroquine, during March May 2020 of the coronavirus (COVID-19) pandemic.
  • Hydroxychloroquine (Plaquenil) and Chloroquine (Aralen) are antimalarials, and hydroxychloroquine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of lupus and rheumatoid arthritis.
  • The survey also found that issues accessing hydroxychloroquine and chloroquine were prevalent across the country, with respondents in California, Florida, New York, Texas and Maryland as the top five states where people with lupus reported issues.
  • For more key findings from the survey, click here and for more information on the coronavirus and lupus visit lupus.org/coronavirus .

Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

Retrieved on: 
Monday, June 22, 2020
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Optical, Other Science, Research, Science, Clinical trials, Medicine, Health, Medical specialties, Immunosuppressants, Peptides, Voclosporin, Kidney diseases, Clinical research, Design of experiments, Nephritis, Systemic lupus erythematosus, Clinical trial, Voclosporin ophthalmic solution (VOS), DES, Aurinia

Following the remaining 12-week treatment period and closing out of clinical trial activities, we look forward to reporting data from this trial in the fourth quarter of this year.

Key Points: 
  • Following the remaining 12-week treatment period and closing out of clinical trial activities, we look forward to reporting data from this trial in the fourth quarter of this year.
  • The AUDREY trial is a randomized, double-masked, vehicle-controlled, dose-ranging study evaluating the efficacy and safety of VOS in subjects with DES.
  • Voclosporin ophthalmic solution (VOS) is an aqueous, preservative free nanomicellar solution intended for use in the treatment of DES.
  • The Company is currently developing the investigational drug voclosporin for the treatment of lupus nephritis, other proteinuric diseases and dry eye syndrome.

Researchers Overdosing COVID-19 Patients on Hydroxychloroquine, States Association of American Physicians & Surgeons (AAPS)

Retrieved on: 
Wednesday, June 17, 2020
Medical specialties, RTT, Medicine, Health, Autoimmune diseases, Rheumatology, Hydroxychloroquine, Quinolines, Association of American Physicians and Surgeons, AAPS, Systemic lupus erythematosus, Rheumatoid arthritis

TUCSON, Ariz., June 17, 2020 /PRNewswire/ --Until President Trump suggested that hydroxychloroquine (HCQ, Plaquenil) might help COVID-19 patients, it was generally considered a very safe drug, observes the Association of American Physicians & Surgeons (AAPS).

Key Points: 
  • TUCSON, Ariz., June 17, 2020 /PRNewswire/ --Until President Trump suggested that hydroxychloroquine (HCQ, Plaquenil) might help COVID-19 patients, it was generally considered a very safe drug, observes the Association of American Physicians & Surgeons (AAPS).
  • It was approved by the FDA in 1955 and has been used by hundreds of millions of patients worldwide for malaria, lupus, and rheumatoid arthritis.
  • Apparently because of alarming media coverage, many patients are now expressing fear that HCQ is dangerous because of cardiac effects, states AAPS.
  • The Association of American Physicians and Surgeons (AAPS) has represented physicians of all specialties in all states since 1943.

Global Hydroxychloroquine Drugs Market (2020 to 2025) - Featuring Novartis AG, Sanofi & Amneal Pharmaceuticals Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 17, 2020
Health, Pharmaceutical, RTT, Chemical compounds, Medicine, Organic compounds, Chloroarenes, Hydroxychloroquine, Quinolines, Autoimmune diseases, Systemic lupus erythematosus, Chronic condition

The "Global Hydroxychloroquine Drugs Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hydroxychloroquine Drugs Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global hydroxychloroquine drugs market is projected to grow at a CAGR of 3.08% to reach US$1,174.129 million by 2025, from US$978.745 million in 2019.
  • Rising prevalence of chronic rheumatoid conditions, malaria, and lupus among the individuals is pushing the demand for hydroxychloroquine drugs.
  • However, as the hydroxychloroquine drugs are not so effective on all types of malaria, it hampers the market growth to some extent.

Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020

Retrieved on: 
Tuesday, June 9, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Medicine, Immunosuppressants, Chemical compounds, Peptides, Voclosporin, Autoimmune diseases, RTT, Mycophenolic acid, Systemic lupus erythematosus, Corticosteroid, Lupus nephritis, Voclosporin, Lupus Nephritis, Aurinia

All patients in the AURORA study were treated with mycophenolate (MMF) and a background of corticosteroids.

Key Points: 
  • All patients in the AURORA study were treated with mycophenolate (MMF) and a background of corticosteroids.
  • Our deep analysis of the comprehensive voclosporin clinical program continues to illustrate its potential as a treatment for lupus nephritis.
  • This data has been submitted to the FDA as part of voclosporins recently completed New Drug Application.
  • Overall mortality in the trial was low, with six deaths observed; one in the voclosporin arm and five in the control group.

SLE Synergy to Commence Trading on the Canadian Securities Exchange

Retrieved on: 
Monday, June 8, 2020
Cutaneous lupus erythematosus, Autoimmune diseases, RTT, Systemic lupus erythematosus, William Osler, Medicine, Medical specialties, Clinical medicine

VANCOUVER, BC, June 8, 2020 /CNW/ -SLE Synergy Ltd. ("SLE" or the "Company"), announces that it has received final approval from the Canadian Securities Exchange (the "CSE") and the Company's common shares (the "Common Shares") will commence trading on the CSE on June 8, 2020 under the symbol "SLE".

Key Points: 
  • VANCOUVER, BC, June 8, 2020 /CNW/ -SLE Synergy Ltd. ("SLE" or the "Company"), announces that it has received final approval from the Canadian Securities Exchange (the "CSE") and the Company's common shares (the "Common Shares") will commence trading on the CSE on June 8, 2020 under the symbol "SLE".
  • It is a tremendous milestone for the Company and I would like to thank the listing team and our partners for their contribution.
  • SLE is developing its solid waste digestion enzyme system, solid waste conversion organic fertilizer, and soil recovery microbe business in China.
  • SLE set foot in Shanghai in 2019, and will look to expand to other neighboring regions in the near future.

Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)

Retrieved on: 
Thursday, June 4, 2020
Medical specialties, RTT, Medicine, Organ systems, Autoimmune diseases, Immunology, Psoriasis, Systemic lupus erythematosus, Autoimmunity, Atopic dermatitis

NKTR-358 was discovered by Nektar and is being co-developed in partnership with Eli Lilly and Company.

Key Points: 
  • NKTR-358 was discovered by Nektar and is being co-developed in partnership with Eli Lilly and Company.
  • "Based upon these data, Nektar and our partner Lilly are advancing NKTR-358 into a Phase 2 studyin patients with moderate to severe SLE, which will be initiated this summer."
  • Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person's body.
  • It is currently being evaluated in two separate Phase 1b studies in patients with atopic dermatitis (NCT04081350) and psoriasis (NCT04119557).